Jinwon Life Sciences Registers Chinese Patent for Next-Generation Transdermal Drug Delivery System

Jinwon Life Sciences announced on the 18th that it has received a patent registration from the China National Intellectual Property Administration (CNIPA) for the self-controlled electrostatic layer-by-layer deposition technology (SLED), a core technology of the coated microneedles in the transdermal drug delivery system currently under development. The patent is filed in multiple countries including the United States, with China being the first country to complete the patent registration.

The SLED technology for microneedles, co-developed with researchers from Rutgers University in New Jersey, USA, is a next-generation transdermal drug delivery system (DDS) that coats drugs onto microneedles for effective transdermal drug delivery. Jinwon Life Sciences holds an exclusive license for all biological uses related to this patent.

This technology uniformly delivers coating materials onto all types of surfaces, including round and irregular surfaces, and can deliver DNA as well as various drugs, proteins, or biologics onto surfaces without loss of function or structure.

Younggeun Park, CEO of Jinwon Life Sciences, stated, “We are pleased to have developed the SLED technology, which can be applied in the field of nanotechnology following the development of Gene-Derm used in the COVID-19 DNA vaccine (GLS-5310) with the research team. With the global interest in microneedle technology and microneedle pharmaceuticals increasing, especially as one of the top 10 future promising technologies selected by the World Economic Forum (WEF) in 2020, the importance of developing coated microneedles is very significant considering the potential applications of the microneedle platform in various fields including vaccines.”

Joel Maslow, Chief Medical Officer (CMO) of Jinwon Life Sciences, explained, “In the case of the low molecular weight immunomodulator GLS-1027 and the hepatitis C vaccine that our company is developing, it has been demonstrated that the structure is perfectly preserved and coated onto microneedles with high efficiency. This enables highly efficient and targeted drug delivery, including DNA and mRNA-based drugs and vaccines.” He added, “The potential applications of SLED technology can be expanded to countless fields such as implantable medical devices coated with agents to limit inflammation and improve function for stents, prosthetic joints, and devices.”

This content was produced with the assistance of AI translation services.